JP2024515809A - Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤の使用による併用療法 - Google Patents

Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤の使用による併用療法 Download PDF

Info

Publication number
JP2024515809A
JP2024515809A JP2023565986A JP2023565986A JP2024515809A JP 2024515809 A JP2024515809 A JP 2024515809A JP 2023565986 A JP2023565986 A JP 2023565986A JP 2023565986 A JP2023565986 A JP 2023565986A JP 2024515809 A JP2024515809 A JP 2024515809A
Authority
JP
Japan
Prior art keywords
cancer
antibody
obi
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515809A5 (https=
Inventor
ライ、ミン－タイン
リー、ワン－フェン
ワン、チュン－チョン
チェン、ルー－ツー
Original Assignee
アセンタウィッツ ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセンタウィッツ ファーマシューティカルズ リミテッド filed Critical アセンタウィッツ ファーマシューティカルズ リミテッド
Publication of JP2024515809A publication Critical patent/JP2024515809A/ja
Publication of JP2024515809A5 publication Critical patent/JP2024515809A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023565986A 2021-04-28 2021-04-28 Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤の使用による併用療法 Pending JP2024515809A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/029552 WO2022231580A1 (en) 2021-04-28 2021-04-28 Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor

Publications (2)

Publication Number Publication Date
JP2024515809A true JP2024515809A (ja) 2024-04-10
JP2024515809A5 JP2024515809A5 (https=) 2024-04-30

Family

ID=83847212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565986A Pending JP2024515809A (ja) 2021-04-28 2021-04-28 Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤の使用による併用療法

Country Status (10)

Country Link
US (1) US20240216401A1 (https=)
EP (1) EP4329745A4 (https=)
JP (1) JP2024515809A (https=)
KR (1) KR20240004519A (https=)
CN (1) CN117729917A (https=)
AU (1) AU2021443620A1 (https=)
BR (1) BR112023020922A2 (https=)
CA (1) CA3216896A1 (https=)
IL (1) IL307974A (https=)
WO (1) WO2022231580A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744168A (zh) * 2022-09-09 2025-04-01 深圳艾欣达伟医药科技有限公司 Ast-3424联用治疗白血病及淋巴瘤
WO2025026214A1 (zh) 2023-07-28 2025-02-06 深圳艾欣达伟医药科技有限公司 治疗p53基因突变或缺陷阴性癌症、肿瘤患者
CN121646469A (zh) 2023-09-05 2026-03-10 深圳艾欣达伟医药科技有限公司 Ast-3424治疗癌症、肿瘤的给药方案及制药用途
CN121049512A (zh) * 2024-05-28 2025-12-02 深圳艾欣达伟医药科技有限公司 Ast-3424治疗肝癌

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125652A1 (ja) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
JP2018517710A (ja) * 2015-11-16 2018-07-05 アセンタ ファーマシューティカルズ リミテッド （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) * 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
JP7194022B2 (ja) * 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
US11098002B2 (en) * 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125652A1 (ja) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
JP2018517710A (ja) * 2015-11-16 2018-07-05 アセンタ ファーマシューティカルズ リミテッド （ｒ）−および（ｓ）−１−（３−（３−ｎ，ｎ−ジメチルアミノカルボニル）フェノキシル−４−ニトロフェニル）−１−エチル−ｎ，ｎ’−ビス（エチレン）ホスホルアミデート、組成物ならびにその使用方法および製造方法

Also Published As

Publication number Publication date
BR112023020922A2 (pt) 2023-12-12
WO2022231580A1 (en) 2022-11-03
EP4329745A4 (en) 2025-03-19
CN117729917A (zh) 2024-03-19
AU2021443620A1 (en) 2023-10-26
CA3216896A1 (en) 2022-11-03
KR20240004519A (ko) 2024-01-11
US20240216401A1 (en) 2024-07-04
IL307974A (en) 2023-12-01
EP4329745A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
JP2024515809A (ja) Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤の使用による併用療法
EP3362074B1 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US20130164283A1 (en) Antibody induced cell membrane wounding
JP6764017B2 (ja) がんの処置での使用のためのコビシスタット
JP2020517652A5 (https=)
US10960008B2 (en) Methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3KBETA and anti-immune checkpoint agents
KR20210137162A (ko) 종양유전자-유발 암의 치료
Eglenen-Polat et al. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer
Mussafi et al. Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
Wallace-Povirk et al. Targeted therapy of pyrrolo [2, 3-d] pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment
Qiao et al. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
US20230173095A1 (en) Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
JP2025179057A (ja) 併用療法のための患者の選択
TW202241455A (zh) 使用akr1c3活化化合物與免疫檢查點抑制劑之組合療法
EP4626887A1 (en) Atropisomers of mat2a inhibitors
US20170131280A1 (en) Methods, assays, and systems relating to sakt
Nemuvumoni An Investigation into the Effects of Metformin in Combination with Clofarabine for the Treatment of Leukaemia Using T-Lymphoblastic Leukaemia Cell Lines
Gray Engineering Reagents to Target the Sialic Acid Glyco-Immune Checkpoint
HK40050163B (en) Selection of patients for combination therapy
HK40050163A (en) Selection of patients for combination therapy
Goemans et al. In-vitro sensitivity to the farnesyltransferase inhibitor R115777 of childhood AML, ALL and normal bone marrow cells
Desai et al. 344 Pharmacological and pharmacokinetic profile of AI1008, a novel and potent inhibitor of abl-kinase activity
Jordanides Expression and function of drug transporters in primitive CML cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260129